TY - JOUR
T1 - The Association between Rate and Severity of Exacerbations in Chronic Obstructive Pulmonary Disease
T2 - An Application of a Joint Frailty-Logistic Model
AU - Sadatsafavi, Mohsen
AU - Sin, Don D.
AU - Zafari, Zafar
AU - Criner, Gerard
AU - Connett, John E.
AU - Lazarus, Stephen
AU - Han, Meilan
AU - Martinez, Fernando
AU - Albert, Richard
N1 - Publisher Copyright:
© 2016 The Author 2016. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Exacerbations are a hallmark of chronic obstructive pulmonary disease (COPD). Evidence suggests the presence of substantial between-individual variability (heterogeneity) in exacerbation rates. The question of whether individuals vary in their tendency towards experiencing severe (versus mild) exacerbations, or whether there is an association between exacerbation rate and severity, has not yet been studied. We used data from the MACRO Study, a 1-year randomized trial of the use of azithromycin for prevention of COPD exacerbations (United States and Canada, 2006-2010; n = 1,107, mean age = 65.2 years, 59.1% male). A parametric frailty model was combined with a logistic regression model, with bivariate random effects capturing heterogeneity in rate and severity. The average rate of exacerbation was 1.53 episodes/year, with 95% of subjects having a model-estimated rate of 0.47-4.22 episodes/year. The overall ratio of severe exacerbations to total exacerbations was 0.22, with 95% of subjects having a model-estimated ratio of 0.04-0.60. We did not confirm an association between exacerbation rate and severity (P = 0.099). A unified model, implemented in standard software, could estimate joint heterogeneity in COPD exacerbation rate and severity and can have applications in similar contexts where inference on event time and intensity is considered. We provide SAS code (SAS Institute, Inc., Cary, North Carolina) and a simulated data set to facilitate further uses of this method.
AB - Exacerbations are a hallmark of chronic obstructive pulmonary disease (COPD). Evidence suggests the presence of substantial between-individual variability (heterogeneity) in exacerbation rates. The question of whether individuals vary in their tendency towards experiencing severe (versus mild) exacerbations, or whether there is an association between exacerbation rate and severity, has not yet been studied. We used data from the MACRO Study, a 1-year randomized trial of the use of azithromycin for prevention of COPD exacerbations (United States and Canada, 2006-2010; n = 1,107, mean age = 65.2 years, 59.1% male). A parametric frailty model was combined with a logistic regression model, with bivariate random effects capturing heterogeneity in rate and severity. The average rate of exacerbation was 1.53 episodes/year, with 95% of subjects having a model-estimated rate of 0.47-4.22 episodes/year. The overall ratio of severe exacerbations to total exacerbations was 0.22, with 95% of subjects having a model-estimated ratio of 0.04-0.60. We did not confirm an association between exacerbation rate and severity (P = 0.099). A unified model, implemented in standard software, could estimate joint heterogeneity in COPD exacerbation rate and severity and can have applications in similar contexts where inference on event time and intensity is considered. We provide SAS code (SAS Institute, Inc., Cary, North Carolina) and a simulated data set to facilitate further uses of this method.
KW - chronic obstructive pulmonary disease
KW - nonlinear mixed models
KW - random effects
KW - randomized trials
KW - survival analysis
UR - http://www.scopus.com/inward/record.url?scp=84994420242&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994420242&partnerID=8YFLogxK
U2 - 10.1093/aje/kww085
DO - 10.1093/aje/kww085
M3 - Article
C2 - 27737842
AN - SCOPUS:84994420242
SN - 0002-9262
VL - 184
SP - 681
EP - 689
JO - American journal of epidemiology
JF - American journal of epidemiology
IS - 9
ER -